<DOC>
	<DOC>NCT01380119</DOC>
	<brief_summary>This is a phase II, randomized, placebo-controlled trial, aimed to seek the therapeutic benefit of V7 in combination with standard of care anti-Tuberculosis (TB) therapy (ATT) among Mycobacterium tuberculosis-infected sputum smear positive subjects. The results will be compared to placebo combined with standard ATT therapy. The trial will consist of one stage with sputum evaluation at months 1 and 2.</brief_summary>
	<brief_title>Tuberculosis (TB) Immunotherapy Phase 2 Study</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>Subjects who are at least 18 years old and are willing and capable of providing informed consent. Both men and nonpregnant women will be included. TB infection documented prior to Study Entry by sputum smear positive for acidfast bacilli (AFB) test. TB score status at baseline. Agreement to participate in the study and to give a sample of blood for lab testing. Readily available home or other address where patient can be found. Subjects who might have already taken V5 in prior trial and have no baseline data. Pregnant or breastfeeding women are excluded. Subjects who have taken study unrelated drugs or immunomodulatory therapies during study or prior to Entry. Medical conditions such as active alcohol or substance abuse, or psychological issues that in the opinion of the local investigator would interfere with adherence to the requirements of this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>sputum conversion</keyword>
	<keyword>liver biochemistry</keyword>
	<keyword>weight loss</keyword>
	<keyword>quality of life</keyword>
</DOC>